Table 4 Interaction terms for tamoxifen effect (ER+/HER2− cohort) for full follow-up

AR

1.11 (0.77–1.58)

0.59 (0.78)

1.14 (0.80–1.64)

0.47 (0.67)

1.26 (0.91–1.76)

0.17 (0.28)

1.33 (0.96–1.86)

0.090 (0.15)

ESR1

1.36 (0.93–1.98)

0.12 (0.30)

1.26 (0.85–1.89)

0.25 (0.63)

1.50 (1.07–2.11)

0.020 (0.050)

1.40 (0.98–1.99)

0.063 (0.15)

FOXA1

1.87 (1.28–2.75)

0.0013 (0.0064)

1.61 (1.08–2.38)

0.018 (0.091)

1.89 (1.34–2.67)

0.00032 (0.0016)

1.72 (1.21–2.46)

0.0027 (0.014)

Mast cells

1.09 (0.76–1.56)

0.66 (0.78)

1.12 (0.78–1.60)

0.54 (0.67)

1.00 (0.74–1.37)

0.98 (0.98)

1.04 (0.76–1.41)

0.83 (0.83)

PGR

0.95 (0.66–1.36)

0.78 (0.78)

1.00 (0.68–1.45)

0.98 (0.98)

1.18 (0.85–1.62)

0.32 (0.40)

1.22 (0.88–1.69)

0.24 (0.30)